Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ) has shared an announcement.
Wuhan YZY Biopharma Co., Ltd. announced interim data from its Phase II clinical trial of M701, a bispecific antibody drug targeting EpCAM and CD3, for treating malignant pleural effusion (MPE) caused by advanced non-small cell lung cancer (NSCLC). The study showed promising results, with the experimental group demonstrating a longer puncture-free survival and higher objective response rate compared to the control group treated with Cisplatin. The findings suggest M701’s potential efficacy and safety, particularly for NSCLC patients without driven gene mutations or those previously treated with intrapleural chemotherapy. A Phase III trial is planned for 2026 to further validate these outcomes.
The most recent analyst rating on (HK:2496) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Wuhan YZY Biopharma Co., Ltd. Class H stock, see the HK:2496 Stock Forecast page.
More about Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of bispecific antibody drugs. The company is engaged in creating innovative treatments for various medical conditions, with a particular emphasis on oncology.
Average Trading Volume: 2,750
Technical Sentiment Signal: Strong Buy
See more insights into 2496 stock on TipRanks’ Stock Analysis page.